CD22 and diffuse large B-cell lymphoma: Among the enrolled patients, 33 with r/r DLBCL patients who had received DFC (decitabine, fludarabine, and cyclophosphamide) lymphodepletion chemotherapy and tandem CD19/CD22 CAR-T cells were evaluated for efficacy and toxicity.